USFDA classifies Lupin’s Somerset facility as ‘Official Action Indicated’
Lupin’s subsidiary — Novel Laboratories’ Somerset facility has been cautioned by the United States Food and Drug Administration (USFDA) that it may be subject to regulatory or administrative action and that it may withhold approval of any pending applications or supplements in which this facility is listed. The US Food and Drug Administration (USFDA) had … Read more
